Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Status Completed

Clinical Trial Summary

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the immune system and stop tumor cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving vaccine therapy together with BCG and sargramostim in treating patients who have undergone cystectomy for transitional cell carcinomas.

Clinical Trial Description

OBJECTIVES: - Determine the safety and tolerability of NY-ESO-1 peptide vaccine, Bacille Calmette Guerin (BCG), and sargramostim (GM-CSF) in post-cystectomy patients with transitional cell carcinoma of the bladder expressing NY-ESO-1 or LAGE-1 antigen. - Determine the immunological profile (NY-ESO-1 antibody, CD8+ cells, and delayed-type hypersensitivity) induced by this regimen in these patients. OUTLINE: This is an open-label, pilot study. Patients receive NY-ESO-1 protein vaccine mixed with BCG intradermally (ID) once weekly on weeks 1 and 2. Patients then receive NY-ESO-1 protein mixed with sargramostim (GM-CSF) ID once weekly on day 2 of weeks 3-6. Patients also receive GM-CSF subcutaneously alone on days 1, 3, 4, and 5 of weeks 3-6. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00070070
Study type	Interventional
Source	Ludwig Institute for Cancer Research
Contact
Status	Completed
Phase	Phase 1
Start date	October 28, 2003
Completion date	September 30, 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03296306` - Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma	Phase 3
Completed	`NCT00880334` - Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC	Phase 2
Completed	`NCT00216801` - Relationship of Ochratoxin A to Upper Urologic Cancers	N/A
Withdrawn	`NCT04179110` - Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor	Phase 2
Completed	`NCT00154687` - Weekly TP-HDFL in the Treatment of Advanced TCC	Phase 2
Completed	`NCT03256877` - Detecting Transitional Cell Carcinoma From Haematuria
Withdrawn	`NCT04006691` - Efficacy and Safety of UGN-101 in Recurrent Patients	Phase 3
Terminated	`NCT05052372` - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Completed	`NCT00714025` - A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy	Phase 2
Terminated	`NCT01310803` - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder	Phase 3
Completed	`NCT00623831` - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen	Phase 1
Completed	`NCT00173862` - Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC	Phase 2
Recruiting	`NCT03896958` - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated	`NCT01438112` - Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer	Phase 2/Phase 3
Completed	`NCT00683059` - Single Agent Abraxane as Second Line Therapy in Bladder Cancer	Phase 2
Recruiting	`NCT04811846` - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood	N/A
Not yet recruiting	`NCT04878250` - Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder	Phase 2
Completed	`NCT00633789` - Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types	Phase 2
Completed	`NCT00612326` - Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging	N/A
Active, not recruiting	`NCT03219775` - Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma	Phase 2